BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 11585361)

  • 1. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells.
    Taverna P; Liu L; Hwang HS; Hanson AJ; Kinsella TJ; Gerson SL
    Mutat Res; 2001 May; 485(4):269-81. PubMed ID: 11585361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.
    Liu L; Taverna P; Whitacre CM; Chatterjee S; Gerson SL
    Clin Cancer Res; 1999 Oct; 5(10):2908-17. PubMed ID: 10537360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Base excision repair as a therapeutic target in colon cancer.
    Liu L; Nakatsuru Y; Gerson SL
    Clin Cancer Res; 2002 Sep; 8(9):2985-91. PubMed ID: 12231545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment with temozolomide and methoxyamine: blocking apurininc/pyrimidinic site repair coupled with targeting topoisomerase IIalpha.
    Yan L; Bulgar A; Miao Y; Mahajan V; Donze JR; Gerson SL; Liu L
    Clin Cancer Res; 2007 Mar; 13(5):1532-9. PubMed ID: 17332299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
    Liu L; Markowitz S; Gerson SL
    Cancer Res; 1996 Dec; 56(23):5375-9. PubMed ID: 8968088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
    Tang JB; Svilar D; Trivedi RN; Wang XH; Goellner EM; Moore B; Hamilton RL; Banze LA; Brown AR; Sobol RW
    Neuro Oncol; 2011 May; 13(5):471-86. PubMed ID: 21377995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
    Wedge SR; Porteous JK; Newlands ES
    Br J Cancer; 1996 Oct; 74(7):1030-6. PubMed ID: 8855970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
    Liu L; Schwartz S; Davis BM; Gerson SL
    Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance.
    Yamauchi T; Ogawa M; Ueda T
    Mol Pharmacol; 2008 Jul; 74(1):82-91. PubMed ID: 18430789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage.
    Ito M; Ohba S; Gaensler K; Ronen SM; Mukherjee J; Pieper RO
    PLoS One; 2013; 8(5):e62351. PubMed ID: 23667469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of hPMC2 imparts chemotherapeutic sensitivity to alkylating agents in breast cancer cells.
    Krishnamurthy N; Liu L; Xiong X; Zhang J; Montano MM
    Cancer Biol Ther; 2015; 16(4):518-27. PubMed ID: 25849309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.
    Curtin NJ; Wang LZ; Yiakouvaki A; Kyle S; Arris CA; Canan-Koch S; Webber SE; Durkacz BW; Calvert HA; Hostomsky Z; Newell DR
    Clin Cancer Res; 2004 Feb; 10(3):881-9. PubMed ID: 14871963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockage of abasic site repair enhances antitumor efficacy of 1,3-bis-(2-chloroethyl)-1-nitrosourea in colon tumor xenografts.
    Liu L; Yan L; Donze JR; Gerson SL
    Mol Cancer Ther; 2003 Oct; 2(10):1061-6. PubMed ID: 14578471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization.
    Taverna P; Hwang HS; Schupp JE; Radivoyevitch T; Session NN; Reddy G; Zarling DA; Kinsella TJ
    Cancer Res; 2003 Feb; 63(4):838-46. PubMed ID: 12591735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
    Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
    Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
    Naumann SC; Roos WP; Jöst E; Belohlavek C; Lennerz V; Schmidt CW; Christmann M; Kaina B
    Br J Cancer; 2009 Jan; 100(2):322-33. PubMed ID: 19127257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin.
    Pepponi R; Marra G; Fuggetta MP; Falcinelli S; Pagani E; Bonmassar E; Jiricny J; D'Atri S
    J Pharmacol Exp Ther; 2003 Feb; 304(2):661-8. PubMed ID: 12538819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
    Spiro T; Liu L; Gerson S
    Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
    Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
    Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells.
    Capolongo L; Belvedere G; D'Incalci M
    Cancer Chemother Pharmacol; 1990; 25(6):430-4. PubMed ID: 2311171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.